Mangoceuticals, Other Stockholder Equity from 2010 to 2025

MGRX Stock   2.38  0.09  3.64%   
Mangoceuticals, Common Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity is likely to outpace its year average in 2025. During the period from 2010 to 2025, Mangoceuticals, Common Other Stockholder Equity regression line of annual values had r-squared of  0.44 and arithmetic mean of  5,368,363. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
34.8 M
Current Value
36.5 M
Quarterly Volatility
12.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 768 K, Interest Expense of 14.4 K or Selling General Administrative of 3.2 M, as well as many indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.14 or PTB Ratio of 0.33. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
  
Check out the analysis of Mangoceuticals, Common Correlation against competitors.

Latest Mangoceuticals, Common's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Mangoceuticals, Common Stock over the last few years. It is Mangoceuticals, Common's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Mangoceuticals, Other Stockholder Equity Regression Statistics

Arithmetic Mean5,368,363
Geometric Mean3,026
Coefficient Of Variation227.15
Mean Deviation8,394,762
Median181.00
Standard Deviation12,194,244
Sample Variance148.7T
Range36.5M
R-Value0.66
Mean Square Error89.2T
R-Squared0.44
Significance0.01
Slope1,698,629
Total Sum of Squares2230.5T

Mangoceuticals, Other Stockholder Equity History

202536.5 M
202434.8 M
202312 M
20222.6 M

About Mangoceuticals, Common Financial Statements

Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity34.8 M36.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.